CorMedix tops Q2 estimates, raises adjusted EBITDA guidance
CorMedix Inc. reported second-quarter adjusted EPS of 29 cents and revenue of $101.9 million, both above consensus, and raised adjusted EBITDA guidance while reaffirming fiscal 2026 sales guidance.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.